학술논문
Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina
Document Type
Original Paper
Author
Rojas, Juan I.; Pappolla, Agustín; Patrucco, Liliana; Cristiano, Edgardo; Miguez, Jimena; Liwacki, Susana; Tkachuk, Verónica; Balbuena, María E.; Vrech, Carlos; Deri, Norma; Correale, Jorge; Marrodan, Mariano; Ysrraelit, María C.; Fiol, Marcela; Leguizamon, Felisa; Luetic, Geraldine; Menichini, María L.; Lopez, Pablo A.; Pettinicchi, Juan Pablo; Criniti, Juan; Caride, Alejandro; Tavolini, Darío; Mainella, Carolina; Zanga, Gisela; Burgos, Marcos; Hryb, Javier; Barboza, Andrés; Lazaro, Luciana; Alonso, Ricardo; Silva, Berenice; Fernández Liguori, Nora; Nadur, Débora; Chercoff, Aníbal; Martinez, Alejandra; Steinberg, Judith; Garcea, Orlando; Carrá, Adriana; Alonso Serena, Marina; Carnero Contentti, Edgar
Source
Neurological Sciences. 44(1):281-286
Subject
Language
English
ISSN
1590-1874
1590-3478
1590-3478
Abstract
The objective was to evaluate time to reach an EDSS of 4, 6, and 7 in NMOSD and MOGAD patients included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03,375,177).Methods: NMOSD patients diagnosed according to 2015 criteria and with MOGAD were identified. Patients with at least 3 years of follow-up and periodic clinical evaluations with EDSS outcomes were included. AQP4-antibody and MOG-antibody status was recorded, and patients were stratified as seropositive and seronegative for AQP4-antibody. EDSS of 4, 6, and 7 were defined as dependent variables. Log rank test was used to identify differences between groups.Results: Registry data was provided for a total of 137 patients. Of these, seventy-five presented AQP4-ab-positive NMOSD, 45 AQP4-ab-negative NMOSD, and 11 MOGAD. AQP4-ab status was determined by cell-based assay (CBA) in 72% of NMOSD patients. MOG-ab status was tested by CBA in all cases. Mean time to EDSS of 4 was 53.6 ± 24.5 vs. 63.1 ± 32.2 vs. 44.7 ± 32 months in seropositive, seronegative NMOSD, and MOGAD, respectively (p = 0.76). Mean time to EDSS of 6 was 79.2 ± 44.3 vs. 75.7 ± 48.6 vs. 54.7 ± 50 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.23), while mean time to EDSS of 7 was 86.8 ± 54 vs. 80.4 ± 51 vs. 58.5 ± 47 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.39).Conclusion: No differences were observed between NMOSD (seropositive and seronegative) and MOGAD in survival curves.